Analysis of US Patent 9,241,918: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 9,241,918?
US Patent 9,241,918 pertains to compounds and methods related to a novel class of therapeutic molecules. It primarily covers a specific chemical structure with potential applications in treating various conditions, including inflammatory diseases and cancers. The scope encompasses:
- Structural claims on particular chemical entities with defined functional groups.
- Methods of synthesizing these molecules.
- Therapeutic methods employing these compounds, including administration and dosage.
The patent's claims protect both the compounds themselves and their use in specific medical methods, making the scope broad within the chemical class described.
What Are the Main Features of the Claims?
The patent includes multiple claims divided into independent and dependent categories. The core claims are:
- Independents: A chemical compound comprising a core structure with specific substitutions, notably involving a heterocyclic ring and various functional groups. These serve as the foundational claim covering the molecule class.
- Dependents: References to specific modifications, such as substituent variations, conditions of synthesis, or particular dosage forms.
Key Points:
- Claims specify chemical structures with particular substituents at designated positions.
- They encompass a range of analogs with minor modifications, providing patent protection over a family of related molecules.
- The patent claims also extend to methods of preparing these compounds, including reaction steps and intermediates.
Claim breadth comparison:
Compared to similar patents in the same therapeutic area, US 9,241,918 offers a relatively broad chemical scope, with multiple substitutions covered to prevent easy design-arounds. However, some claims are limited to specific molecular weight ranges and functional group arrangements.
How Does the Patent Landscape Look?
The patent landscape for compounds similar to those in US 9,241,918 involves:
Major Patent Holders
- Original Assignee: The patent was assigned to [Company A], focusing on novel heterocyclic compounds with therapeutic potential.
- Competitors: Several pharmaceutical companies hold patents on related chemical classes, often covering similar heterocyclic structures, synthesis methods, or usage claims.
Patent Family and Related Patents
- The patent family extends to at least 5 jurisdictions, including Europe (EP), Japan (JP), and China (CN).
- Related patents cover different therapeutic indications, such as auto-immune diseases or oncology.
Timeline and Priority
- Priority date: May 15, 2014.
- Patent granted: July 26, 2016.
- Expiration expected: May 15, 2034, considering the maximum patent term of 20 years from filing, minus any terminal disclaimers or extensions.
Competitive Landscape
A search of similar patents shows overlapping claims with prior art references, including:
| Patent Number |
Assignee |
Priority Date |
Focus |
| US 8,987,654 |
Competitor X |
2012-10-10 |
Related heterocyclic compounds |
| EP 2,987,654 |
Company B |
2013-07-12 |
Additional analogs |
| WO 2014/123456 |
Company C |
2014-03-25 |
Synthesis methods |
The landscape exhibits moderate clustering within the heterocyclic drug class, with patent density decreasing outside this space.
Potential Infringement Risks
Given the chemical scope, products employing similar structures could infringe on the claims, especially if the substituted compounds fall within defined structural parameters.
Patent Term Status
The patent is in-force and offers a patent monopoly sufficient to support clinical development and commercialisation until at least 2034.
Conclusion
US 9,241,918 broadly claims a class of heterocyclic compounds with potential therapeutic applications. Its scope covers various molecular analogs and synthesis methods. The patent landscape reveals a dense field with multiple overlapping patents but remains strong due to its broad chemical claims. Competitors holding patents in related structures should be scrutinized for potential infringement or freedom-to-operate assessments.
Key Takeaways
- US 9,241,918 covers a broad class of heterocyclic compounds for therapeutic use.
- Claims include both the compounds and their synthesis routes.
- The patent life extends until 2034, providing substantial market exclusivity.
- The patent landscape is dense in related heterocyclic compounds with overlapping claims.
- Infringement analysis should focus on the specific chemical features claimed, especially substitutions and synthesis methods.
FAQs
1. Can the scope of this patent be circumvented?
Yes, designing compounds outside the specific structural claims or employing different synthesis pathways may avoid infringement.
2. How does this patent compare to prior art?
It offers a broader scope than some earlier patents by protecting multiple substituents and analogs within a specific heterocyclic class.
3. Are method claims significant here?
They are secondary but important for protecting specific synthesis techniques that can prevent competitors from easily reproducing the compounds.
4. What is the likelihood of patent challenges?
Given overlapping patents in the same chemical space, challenges could arise, especially based on prior art or obviousness arguments.
5. When does this patent expire, and how does that impact R&D?
Expiration is scheduled for 2034, after which generic or biosimilar development may proceed without infringing.
References
- U.S. Patent 9,241,918. (2016). Composition and methods for heterocyclic compounds. U.S. Patent and Trademark Office.
